Immunitybio, Inc.

This large, late-stage study is testing whether adding a new immunotherapy drug (nogapendekin alfa inbakicept) to standard first-line treatments can better control advanced non-small cell lung cancer. It is enrolling over 1,500 adults who have not yet received treatment for their…

This early-stage study is testing a new cell therapy called PD-L1 t-haNK in adults with advanced solid cancers that have spread or can't be surgically removed. The main goals are to find the safest dose and check for side effects in a small group of 16 participants who have alrea…

This study is testing a new combination treatment for people with high-grade bladder cancer that has not responded to the standard BCG therapy. The treatment involves placing a liquid containing BCG and/or a drug called N-803 directly into the bladder through a catheter. The goal…

This study is testing a new combination of immune-boosting drugs for people with advanced cancers whose disease has progressed after treatment with standard immunotherapies like pembrolizumab or nivolumab. It aims to see if adding a drug called NAI to other treatments can help sh…

This is a first-in-human study to check the safety of a new, personalized cell therapy called M-CENK, given with a drug named N-803, for adults with advanced solid tumors that have spread or stopped responding to other treatments. The therapy involves collecting a patient's own i…

This study is testing whether adding a combination of three immunotherapy drugs to standard chemotherapy works better than chemotherapy alone for people with advanced pancreatic cancer that cannot be removed by surgery. It involves 328 adults whose cancer has progressed after pre…

This is an early safety study to find the highest safe dose and identify side effects of an experimental drug called IBRX-042 for people with HPV-related cancers that have returned or progressed. It will involve about 12 participants who have already tried standard treatments. Th…